Predictors of Improved CVD Risk Factors After Bariatric Sx ID'd
WEDNESDAY, Jan. 10, 2018 -- Increased weight loss, female sex, and younger age predict increased probability of resolution of specific cardiovascular disease risk factors (CVD-RFs) in adolescents undergoing metabolic and bariatric surgery (MBS), according to a study published online Jan. 8 in Pediatrics.
Marc P. Michalsky, M.D., from The Ohio State University in Columbus, and colleagues collected anthropometric and health status data on 242 adolescents undergoing MBS at five centers. The authors examined predictors of change in CVD-RFs (blood pressure, lipids, glucose homeostasis, and inflammation) three years after Roux-en-Y gastric bypass and vertical sleeve gastrectomy.
The researchers found that increasing weight loss independently predicted normalization in dyslipidemia, elevated blood pressure, hyperinsulinemia, diabetes, and elevated high-sensitivity C-reactive protein. Dyslipidemia resolution was less likely for older versus younger participants at the time of surgery; improvements in elevated blood pressure were more likely for girls than boys. Over time there were significant improvements in lipid and blood pressure values even for those participants without frank dyslipidemia or elevated blood pressure at baseline.
"Numerous CVD-RFs improve among adolescents undergoing MBS," the authors write. "The elucidation of predictors of change in CVD-RFs may lead to refinements in patient selection and optimal timing of adolescent bariatric surgery designed to improve clinical outcomes."
Several authors disclosed financial ties to medical device companies.
© 2020 HealthDay. All rights reserved.
Posted: January 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.